Benzimidazol-2-ylidene Gold(I) Complexes Are Thioredoxin Reductase Inhibitors with Multiple Antitumor Properties

Riccardo Rubbiani(Technische Universität Braunschweig), Igor Kitanović(Heidelberg University), Hamed Alborzinia(Heidelberg University), Suzan Can(Heidelberg University), Ana Kitanovic(Heidelberg University), Liliane A. Onambele(University Hospital Cologne), Maria Stefanopoulou(Ruhr University Bochum), Y. Geldmacher(Ruhr University Bochum), William S. Sheldrick(Ruhr University Bochum), Gerhard Wolber(Freie Universität Berlin), Aram Prokop(University Hospital Cologne), Stefan Wölfl(Heidelberg University), Ingo Ott(Technische Universität Braunschweig)
Journal of Medicinal Chemistry
November 17, 2010
Cited by 320

Abstract

Gold(I) complexes such as auranofin have been used for decades to treat symptoms of rheumatoid arthritis and have also demonstrated a considerable potential as new anticancer drugs. The enzyme thioredoxin reductase (TrxR) is considered as the most relevant molecular target for these species. The here investigated gold(I) complexes with benzimidazole derived N-heterocyclic carbene (NHC) ligands represent a promising class of gold coordination compounds with a good stability against the thiol glutathione. TrxR was selectively inhibited by in comparison to the closely related enzyme glutathione reductase, and all complexes triggered significant antiproliferative effects in cultured tumor cells. More detailed studies on a selected complex revealed a distinct pharmacodynamic profile including the high increase of reactive oxygen species formation, apoptosis induction, strong effects on cellular metabolism (related to cell surface properties, respiration, and glycolysis), inhibition of mitochondrial respiration and activity against resistant cell lines.


Related Papers

No related papers found

Powered by citation graph analysis